These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30981844)

  • 1. The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma.
    Bracke A; Van Elzen R; Van Der Veken P; Augustyns K; De Meester I; Lambeir AM
    Clin Chim Acta; 2019 Aug; 495():154-160. PubMed ID: 30981844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2).
    Vliegen G; Kehoe K; Bracke A; De Hert E; Verkerk R; Fransen E; Jongers B'; Peters E; Lambeir AM; Kumar-Singh S; Pickkers P; Jorens PG; De Meester I
    PLoS One; 2020; 15(4):e0231555. PubMed ID: 32315321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
    Ryabtsova O; Jansen K; Van Goethem S; Joossens J; Cheng JD; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    Bioorg Med Chem Lett; 2012 May; 22(10):3412-7. PubMed ID: 22525314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating concentrations of fibroblast activation protein α in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA.
    Tillmanns J; Widera C; Habbaba Y; Galuppo P; Kempf T; Wollert KC; Bauersachs J
    Int J Cardiol; 2013 Oct; 168(4):3926-31. PubMed ID: 23932048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients.
    Bracke A; De Hert E; De Bruyn M; Claesen K; Vliegen G; Vujkovic A; van Petersen L; De Winter FHR; Hotterbeekx A; Brosius I; Theunissen C; Van Ierssel S; van Frankenhuijsen M; Vlieghe E; Vercauteren K; Van der Veken P; Hendriks D; Kumar-Singh S; De Meester I
    Clin Chim Acta; 2022 Jun; 531():4-11. PubMed ID: 35283094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.
    Edosada CY; Quan C; Wiesmann C; Tran T; Sutherlin D; Reynolds M; Elliott JM; Raab H; Fairbrother W; Wolf BB
    J Biol Chem; 2006 Mar; 281(11):7437-44. PubMed ID: 16410248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).
    Bainbridge TW; Dunshee DR; Kljavin NM; Skelton NJ; Sonoda J; Ernst JA
    Sci Rep; 2017 Oct; 7(1):12524. PubMed ID: 28970566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.
    Jansen K; Heirbaut L; Cheng JD; Joossens J; Ryabtsova O; Cos P; Maes L; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    ACS Med Chem Lett; 2013 May; 4(5):491-6. PubMed ID: 24900696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.
    Nagatsu T
    J Neural Transm (Vienna); 2017 Jun; 124(6):739-744. PubMed ID: 27503084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity.
    Baerts L; Brouns R; Kehoe K; Verkerk R; Engelborghs S; De Deyn PP; Hendriks D; De Meester I
    Transl Stroke Res; 2017 Apr; 8(2):157-164. PubMed ID: 27561653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI.
    Tillmanns J; Fraccarollo D; Galuppo P; Wollert KC; Bauersachs J
    Int J Cardiol; 2017 Apr; 232():155-159. PubMed ID: 28082091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.
    Poplawski SE; Lai JH; Li Y; Jin Z; Liu Y; Wu W; Wu Y; Zhou Y; Sudmeier JL; Sanford DG; Bachovchin WW
    J Med Chem; 2013 May; 56(9):3467-77. PubMed ID: 23594271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).
    Jansen K; Heirbaut L; Verkerk R; Cheng JD; Joossens J; Cos P; Maes L; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    J Med Chem; 2014 Apr; 57(7):3053-74. PubMed ID: 24617858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
    Wong PF; Gall MG; Bachovchin WW; McCaughan GW; Keane FM; Gorrell MD
    Peptides; 2016 Jan; 75():80-95. PubMed ID: 26621486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
    Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
    Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and initial characterisation of a N-benzyloxycarbonyl-prolyl-prolinal (Z-Pro-prolinal)-insensitive 7-(N-benzyloxycarbonyl-glycyl-prolyl-amido)-4-methylcoumarin (Z-Gly-Pro-NH-Mec)-hydrolysing peptidase in bovine serum.
    Cunningham DF; O'Connor B
    Eur J Biochem; 1997 Mar; 244(3):900-3. PubMed ID: 9108263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α.
    Keane FM; Nadvi NA; Yao TW; Gorrell MD
    FEBS J; 2011 Apr; 278(8):1316-32. PubMed ID: 21314817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.
    Dienus K; Bayat A; Gilmore BF; Seifert O
    Arch Dermatol Res; 2010 Dec; 302(10):725-31. PubMed ID: 20872224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adipose tissue contribution to plasma fibroblast growth factor 21 and fibroblast activation protein in obesity.
    van Baak MA; Vink RG; Roumans NJT; Cheng CC; Adams AC; Mariman ECM
    Int J Obes (Lond); 2020 Feb; 44(2):544-547. PubMed ID: 31455871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.
    Meadows SA; Edosada CY; Mayeda M; Tran T; Quan C; Raab H; Wiesmann C; Wolf BB
    Biochemistry; 2007 Apr; 46(15):4598-605. PubMed ID: 17381073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.